HCM
CYTK icon

Harvey Capital Management’s Cytokinetics CYTK Stock Holding History

Harvey Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.82M Buy
68,275
+18,980
+39% +$1.36M 1.2% 25
2026
Q1 		$3.25M Buy
49,295
+2,485
+5% +$158K 0.74% 41
2025
Q4 		$2.97M Buy
46,810
+25,480
+119% +$1.59M 0.63% 41
2025
Q3 		$1.17M Sell
21,330
-600
-3% -$24.7K 0.25% 53
2025
Q2 		$738K Sell
21,930
-650
-3% -$22.6K 0.17% 58
2025
Q1 		$907K Buy
22,580
+475
+2% +$21.8K 0.24% 55
2024
Q4 		$1.04M Buy
+22,105
New +$1.15M 0.24% 53

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harvey Capital Management's CYTK Position: Q2 2026 in Review

Harvey Capital Management increased its Cytokinetics (CYTK) stake by 39% in Q2 2026, buying an estimated $1.36M and bringing the position to 68,275 shares worth $5.82M. The position accounts for 1.2% of the portfolio, ranked #25.

Harvey Capital Management first reported a position in CYTK in Q4 2024 and has held it in 7 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Harvey Capital Management held 68,275 shares of Cytokinetics worth $5.82M as of Q2 2026.
  • Harvey Capital Management bought 18,980 Cytokinetics shares in Q2 2026, an estimated $1.36M.
  • Cytokinetics made up 1.2% of Harvey Capital Management's portfolio in Q2 2026, its #25 holding.
  • Harvey Capital Management first reported a position in Cytokinetics in Q4 2024 and has held it in 7 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Harvey Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.